Shandong Xinhua Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shandong Xinhua Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	11.0%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Jun 28

Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Jan 23

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Mar 07

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 18

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Jul 27

Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Jul 04

Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)

Mar 09

We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt

Dec 21

Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?

Apr 06

What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?

Mar 19

Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?

Feb 26

Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 05

Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years

Jan 18

Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?

Dec 29

Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?

Dec 14

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 26

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shandong Xinhua Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:719 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	8,337	449	169	443	N/A
6/30/2024	8,161	492	20	323	N/A
3/31/2024	7,936	487	166	487	N/A
12/31/2023	8,101	497	-60	265	N/A
9/30/2023	8,547	510	349	601	N/A
6/30/2023	8,511	486	337	584	N/A
3/31/2023	8,311	454	353	592	N/A
1/1/2023	7,503	411	513	758	N/A
9/30/2022	7,073	357	5	263	N/A
6/30/2022	6,673	343	32	289	N/A
3/31/2022	6,623	357	-107	152	N/A
12/31/2021	6,560	349	10	259	N/A
9/30/2021	6,307	364	-19	248	N/A
6/30/2021	6,271	353	107	385	N/A
3/31/2021	6,068	339	123	405	N/A
12/31/2020	6,006	325	140	420	N/A
9/30/2020	5,814	305	208	453	N/A
6/30/2020	5,769	323	75	392	N/A
3/31/2020	5,682	310	69	399	N/A
12/31/2019	5,606	300	-18	348	N/A
9/30/2019	5,716	303	3	480	N/A
6/30/2019	5,680	281	-85	344	N/A
3/31/2019	5,457	264	-26	382	N/A
12/31/2018	5,245	255	-65	324	N/A
9/30/2018	5,023	229	60	339	N/A
6/30/2018	4,800	226	N/A	517	N/A
3/31/2018	4,638	226	N/A	332	N/A
12/31/2017	4,516	210	N/A	390	N/A
9/30/2017	4,491	207	N/A	391	N/A
6/30/2017	4,420	183	N/A	365	N/A
3/31/2017	4,306	154	N/A	446	N/A
12/31/2016	4,015	122	N/A	439	N/A
9/30/2016	3,800	110	N/A	388	N/A
6/30/2016	3,647	103	N/A	359	N/A
3/31/2016	3,602	89	N/A	414	N/A
12/31/2015	3,597	83	N/A	349	N/A
9/30/2015	3,604	64	N/A	304	N/A
6/30/2015	3,678	36	N/A	284	N/A
3/31/2015	3,653	62	N/A	266	N/A
12/31/2014	3,590	51	N/A	346	N/A
9/30/2014	3,769	52	N/A	N/A	N/A
6/30/2014	3,635	74	N/A	235	N/A
3/31/2014	3,588	50	N/A	290	N/A
12/31/2013	3,391	39	N/A	105	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 719's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 719's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 719's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 719's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 719's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 719's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 23:57
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shandong Xinhua Pharmaceutical Company Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Alex Fan	GF Securities (Hong Kong) Brokerage Limited
Ming Li	Industrial Securities Co. Ltd.
Guohe Fan	Phillip Securities (HK)

Shandong Xinhua Pharmaceutical Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) signed an equity acquisition intention agreement to acquire 75% stake in Novosana (Taicang) Bio Feed Co., Ltd. from Novosana (Europe) B.V.

Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation

Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 3Q 2023)

Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application

Investor sentiment improves as stock rises 16%

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024

Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application

Shandong Xinhua Pharmaceutical Company Limited Announces Esomeprazole Magnesium Obtains the Notification of Approval of Marketing Application for Chemical Substance Drugs

Upcoming dividend of HK$0.027 per share

Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 2Q 2023)

Shandong Xinhua Pharmaceutical Company Limited Announces Interim Dividend, Payable on or Before 27 September 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 30 July 2024

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 23, 2024

Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Dividend of HK$0.27 announced

Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.23 in 1Q 2023)

Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥0.74 (vs CN¥0.62 in FY 2022)

Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023

Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient

Now 21% overvalued

Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate

Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 29, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes

Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg)

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2022)

Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat

Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 2Q 2022)

Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee

Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023

Shandong Xinhua Pharmaceutical Company Limited Announces Rabeprazole Sodium Enteric-coated Tablets (20mg) Passing the GenericsConsistency Evaluation

Shandong Xinhua Pharmaceutical Company Limited Announces on New Drug Specifications and Passing the Generics Consistency Evaluation

Upcoming dividend of HK$0.22 per share at 3.6% yield

Shandong Xinhua Pharmaceutical Company Limited Obtains Alogliptin Benzoate Approval of Marketing Application for Chemical Raw Material Drugs

Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Full year 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.56 in FY 2021)

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Investor sentiment improves as stock rises 24%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Less than half of directors are independent

Investor sentiment improved over the past week

Shandong Xinhua Pharmaceutical Company Limited Approves Board Appointments

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 3Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2022 Results on Oct 25, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces Board Changes

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 2Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 30, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 05 August 2022

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.18 per share

Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Du Deping as Executive Director and General Manager

Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 5 August 2022

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Shandong Xinhua Pharmaceutical Company Limited Proposes to Omit Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.56 (vs CN¥0.52 in FY 2020)

Now 21% undervalued after recent price drop

Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)

We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.14 in 2Q 2020)